Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue (2016 - 2017)

Amphastar Pharmaceuticals has reported Non-Current Deffered Revenue over the past 5 years, most recently at $1.2 million for Q3 2017.

  • Quarterly results put Non-Current Deffered Revenue at $1.2 million for Q3 2017, up 623.21% from a year ago — trailing twelve months through Sep 2017 was $1.2 million (up 623.21% YoY), and the annual figure for FY2016 was $97000.0, down 92.76%.
  • Non-Current Deffered Revenue for Q3 2017 was $1.2 million at Amphastar Pharmaceuticals, up from $423000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for AMPH hit a ceiling of $2.6 million in Q4 2013 and a floor of $97000.0 in Q4 2016.
  • Median Non-Current Deffered Revenue over the past 5 years was $1.3 million (2015), compared with a mean of $1.3 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 92.76% in 2016 and later surged 623.21% in 2017.
  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue stood at $2.6 million in 2013, then dropped by 24.5% to $2.0 million in 2014, then tumbled by 32.44% to $1.3 million in 2015, then plummeted by 92.76% to $97000.0 in 2016, then surged by 1152.58% to $1.2 million in 2017.
  • The last three reported values for Non-Current Deffered Revenue were $1.2 million (Q3 2017), $423000.0 (Q2 2017), and $280000.0 (Q1 2017) per Business Quant data.